About BioNTech SE
https://www.biontech.deBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
CEO
Ugur Sahin
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 83
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
B of A Securities
Buy
Truist Securities
Buy
Citigroup
Buy
Canaccord Genuity
Buy
BMO Capital
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:242.52M
Value:$26.46B
BAILLIE GIFFORD & CO
Shares:7.88M
Value:$859.8M
FMR LLC
Shares:5.45M
Value:$595.08M
Summary
Showing Top 3 of 308
About BioNTech SE
https://www.biontech.deBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.52B ▲ | $1.42B ▲ | $-28.7M ▲ | -1.89% ▲ | $-0.12 ▲ | $149.3M ▲ |
| Q2-2025 | $260.8M ▲ | $685.5M ▲ | $-386.6M ▲ | -148.24% ▲ | $-1.6 ▲ | $-348.3M ▲ |
| Q1-2025 | $182.8M ▼ | $633.1M ▼ | $-415.8M ▼ | -227.46% ▼ | $-1.73 ▼ | $-368.7M ▼ |
| Q4-2024 | $1.19B ▼ | $797.9M ▼ | $259.5M ▲ | 21.81% ▲ | $1.08 ▲ | $464.4M ▲ |
| Q3-2024 | $1.24B | $1.06B | $198.1M | 15.91% | $0.83 | $211.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $14.53B ▲ | $21.34B ▼ | $2.86B ▼ | $18.48B ▼ |
| Q2-2025 | $14.04B ▼ | $21.64B ▲ | $3.13B ▲ | $18.51B ▼ |
| Q1-2025 | $14.11B ▼ | $21.18B ▼ | $2.26B ▼ | $18.93B ▼ |
| Q4-2024 | $16.78B ▲ | $22.53B ▲ | $3.12B ▼ | $19.41B ▲ |
| Q3-2024 | $16.71B | $22.4B | $3.29B | $19.11B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-33.54M ▲ | $854.59M ▲ | $-995.85M ▼ | $-14.03M ▲ | $-195.7M ▼ | $811.14M ▲ |
| Q2-2025 | $-438.53M ▼ | $132.14M ▲ | $-26.67M ▼ | $-14.94M ▼ | $1.05B ▲ | $700.04M ▲ |
| Q1-2025 | $-437.61M ▼ | $-821.66M ▼ | $1.31B ▲ | $-14.52M ▼ | $893.28M ▲ | $-1.47B ▼ |
| Q4-2024 | $276.81M ▲ | $-501.21M ▲ | $649.24M ▲ | $-8.09M ▲ | $-633.09M ▼ | $-601.69M ▲ |
| Q3-2024 | $217.62M | $-687.85M | $-162.62M | $-8.66M | $-379.69M | $-778.73M |
CEO
Ugur Sahin
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 83
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
B of A Securities
Buy
Truist Securities
Buy
Citigroup
Buy
Canaccord Genuity
Buy
BMO Capital
Outperform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:242.52M
Value:$26.46B
BAILLIE GIFFORD & CO
Shares:7.88M
Value:$859.8M
FMR LLC
Shares:5.45M
Value:$595.08M
Summary
Showing Top 3 of 308